Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer

NCT05158062 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Ovarian Epithelial

Interventions

BIOLOGICAL: pembrolizumab
DRUG: olaparib
BIOLOGICAL: bevacizumab
DRUG: carboplatin
DRUG: paclitaxel
DRUG: docetaxel

Sponsor

Kosei Hasegawa, MD, PhD